Literature DB >> 18194202

Function and expression of melatonin receptors on human pancreatic islets.

Reshma D Ramracheya1, Dany S Muller, Paul E Squires, Helen Brereton, David Sugden, Guo Cai Huang, Stephanie A Amiel, Peter M Jones, Shanta J Persaud.   

Abstract

Melatonin is known to inhibit insulin secretion from rodent beta-cells through interactions with cell-surface MT1 and/or MT2 receptors, but the function of this hormone in human islets of Langerhans is not known. In the current study, melatonin receptor expression by human islets was examined by reverse transcription-polymerase chain reaction (RT-PCR) and the effects of exogenous melatonin on intracellular calcium ([Ca2+]i) levels and islet hormone secretion were determined by single cell microfluorimetry and radioimmunoassay, respectively. RT-PCR amplifications indicated that human islets express mRNAs coding for MT1 and MT2 melatonin receptors, although MT2 mRNA expression was very low. Analysis of MT1 receptor mRNA expression at the single cell level indicated that it was expressed by human islet alpha-cells, but not by beta-cells. Exogenous melatonin stimulated increases in intracellular calcium ([Ca2+]i) in dissociated human islet cells, and stimulated glucagon secretion from perifused human islets. It also stimulated insulin secretion and this was most probably a consequence of glucagon acting in a paracrine fashion to stimulate beta-cells as the MT1 receptor was absent in beta-cells. Melatonin did not decrease 3', 5'-cyclic adenosine monophosphate (cyclic AMP) levels in human islets, but it inhibited cyclic AMP in the mouse insulinoma (MIN6) beta-cell line and it also inhibited glucose-stimulated insulin secretion from MIN6 cells. These data suggest that melatonin has direct stimulatory effects at human islet alpha-cells and that it stimulates insulin secretion as a consequence of elevated glucagon release. This study also indicates that the effects of melatonin are species-specific with primarily an inhibitory role in rodent beta-cells and a stimulatory effect in human islets.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18194202     DOI: 10.1111/j.1600-079X.2007.00523.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  53 in total

Review 1.  Melatonin membrane receptors in peripheral tissues: distribution and functions.

Authors:  Radomir M Slominski; Russel J Reiter; Natalia Schlabritz-Loutsevitch; Rennolds S Ostrom; Andrzej T Slominski
Journal:  Mol Cell Endocrinol       Date:  2012-01-08       Impact factor: 4.102

2.  Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.

Authors:  Rüdiger Hardeland
Journal:  Aging Dis       Date:  2011-02-10       Impact factor: 6.745

3.  The insulin-melatonin antagonism: studies in the LEW.1AR1-iddm rat (an animal model of human type 1 diabetes mellitus).

Authors:  E Peschke; K Hofmann; I Bähr; S Streck; E Albrecht; D Wedekind; E Mühlbauer
Journal:  Diabetologia       Date:  2011-04-15       Impact factor: 10.122

Review 4.  Melatonin receptors: molecular pharmacology and signalling in the context of system bias.

Authors:  Erika Cecon; Atsuro Oishi; Ralf Jockers
Journal:  Br J Pharmacol       Date:  2017-08-17       Impact factor: 8.739

Review 5.  Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications.

Authors:  Mariana Murea; Lijun Ma; Barry I Freedman
Journal:  Rev Diabet Stud       Date:  2012-05-10

Review 6.  Insights into pancreatic islet cell dysfunction from type 2 diabetes mellitus genetics.

Authors:  Nicole A J Krentz; Anna L Gloyn
Journal:  Nat Rev Endocrinol       Date:  2020-02-25       Impact factor: 43.330

7.  MTNR1B rs10830963 is associated with fasting plasma glucose, HbA1C and impaired beta-cell function in Chinese Hans from Shanghai.

Authors:  Chen Liu; Ying Wu; Huaixing Li; Qibin Qi; Claudia Langenberg; Ruth J F Loos; Xu Lin
Journal:  BMC Med Genet       Date:  2010-04-14       Impact factor: 2.103

8.  G-allele of intronic rs10830963 in MTNR1B confers increased risk of impaired fasting glycemia and type 2 diabetes through an impaired glucose-stimulated insulin release: studies involving 19,605 Europeans.

Authors:  Thomas Sparsø; Amélie Bonnefond; Ehm Andersson; Nabila Bouatia-Naji; Johan Holmkvist; Lise Wegner; Niels Grarup; Anette P Gjesing; Karina Banasik; Christine Cavalcanti-Proença; Marion Marchand; Martine Vaxillaire; Guillaume Charpentier; Marjo-Riitta Jarvelin; Jean Tichet; Beverley Balkau; Michel Marre; Claire Lévy-Marchal; Kristine Faerch; Knut Borch-Johnsen; Torben Jørgensen; Sten Madsbad; Pernille Poulsen; Allan Vaag; Christian Dina; Torben Hansen; Oluf Pedersen; Philippe Froguel
Journal:  Diabetes       Date:  2009-03-26       Impact factor: 9.461

9.  Common genetic variation in the melatonin receptor 1B gene (MTNR1B) is associated with decreased early-phase insulin response.

Authors:  C Langenberg; L Pascoe; A Mari; A Tura; M Laakso; T M Frayling; I Barroso; R J F Loos; N J Wareham; M Walker
Journal:  Diabetologia       Date:  2009-05-20       Impact factor: 10.122

10.  Common genetic variation near melatonin receptor MTNR1B contributes to raised plasma glucose and increased risk of type 2 diabetes among Indian Asians and European Caucasians.

Authors:  John C Chambers; Weihua Zhang; Delilah Zabaneh; Joban Sehmi; Piyush Jain; Mark I McCarthy; Philippe Froguel; Aimo Ruokonen; David Balding; Marjo-Riitta Jarvelin; James Scott; Paul Elliott; Jaspal S Kooner
Journal:  Diabetes       Date:  2009-08-03       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.